单侧基因治疗注射对Leber遗传性视神经病变的双侧视力改善
REVERSE是一项随机、双盲、假手术对照的多中心3期临床试验,评估单次玻璃体内注射rAAV2/2-ND4对LHON伴视力丧失受试者的疗效。37例携带m.11778G>A突变的受试者接受治疗,右眼随机分配至rAAV2/2-ND4或假注射,左眼接受另一干预。结果两眼在96周随访期内均出现持续视力改善,主要终点未达到(P=0.894),非人灵长类研究提示病毒载体DNA可转移至对侧眼。
要点
- 单侧注射rAAV2/2-ND4后,双眼在96周内均出现持续BCVA改善。
- 第96周时,68%受试者至少一眼有临床相关BCVA恢复,78%双眼视力改善。
- 主要终点未达到:第48周两组BCVA变化差异无统计学意义(P=0.894)。
核心结论
- 单侧玻璃体内注射rAAV2/2-ND4后,LHON受试者双眼均出现持续视力改善,主要终点未达到。
研究设计与样本
- REVERSE为随机、双盲、假手术对照的多中心3期临床试验,共37例携带m.11778G>A突变、视力丧失6至12个月的受试者。
- 每位受试者右眼按1:1随机分配至rAAV2/2-ND4(GS010)或假注射,左眼接受另一干预。
主要发现
- 96周随访期间,双眼均观察到持续视力改善。
- 第96周时,rAAV2/2-ND4治疗眼BCVA平均改善-0.308 LogMAR(+15 ETDRS字母)。
- 第96周时,假注射眼BCVA平均改善-0.259 LogMAR(+13 ETDRS字母)。
- 第96周时,25例(68%)受试者至少一眼BCVA较基线有临床相关恢复,29例(78%)双眼视力改善。
- 非人灵长类研究显示病毒载体DNA从注射眼转移至对侧眼前段、视网膜和视神经。
关键数值与推荐
- 主要终点为第48周两组间BCVA自基线变化差异,结果未达到(P=0.894)。
临床怎么用
- 单侧注射rAAV2/2-ND4后需关注双眼视力变化,对侧眼改善可能影响疗效评估。
局限性
- 主要终点未达到,双侧改善机制需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
REVERSE is a randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial that evaluated the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON). A total of 37 subjects carrying the m.11778G>A (MT-ND4) mutation and with duration of vision loss between 6 to 12 months were treated. Each subject's right eye was randomly assigned in a 1:1 ratio to treatment with rAAV2/2-ND4 (GS010) or sham injection. The left eye received the treatment not allocated to the right eye. Unexpectedly, sustained visual improvement was observed in both eyes over the 96-week follow-up period. At week 96, rAAV2/2-ND4-treated eyes showed a mean improvement in best-corrected visual acuity (BCVA) of -0.308 LogMAR (+15 ETDRS letters). A mean improvement of -0.259 LogMAR (+13 ETDRS letters) was observed in the sham-treated eyes. Consequently, the primary end point, defined as the difference in the change in BCVA from baseline to week 48 between the two treatment groups, was not met (P = 0.894). At week 96, 25 subjects (68%) had a clinically relevant recovery in BCVA from baseline in at least one eye, and 29 subjects (78%) had an improvement in vision in both eyes. A nonhuman primate study was conducted to investigate this bilateral improvement. Evidence of transfer of viral vector DNA from the injected eye to the anterior segment, retina, and optic nerve of the contralateral noninjected eye supports a plausible mechanistic explanation for the unexpected bilateral improvement in visual function after unilateral injection.
引用
- Yu-Wai-Man P, Newman NJ, Carelli V, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020. PMID: 33298565. doi:10.1126/scitranslmed.aaz7423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。